Key Highlights

  • EyePoint (NASDAQ: EYPT) agreed to pay to settle U.S. Department of Justice allegations tied to DEXYCU marketing practices.
  • The settlement resolves claims under the False Claims Act, Civil Monetary Penalties Law, and other statutes without admission of liability.
  • The company also entered a Corporate Integrity Agreement with HHS, requiring compliance program overhauls.
  • The deal removes the risk of exclusion from Medicare and Medicaid programs.

The settlement, disclosed in a regulatory filing, closes a probe by the U.S. Department of Justice and the Office of Inspector General without the company admitting wrongdoing. EyePoint will also enter a Corporate Integrity Agreement with the Department of Health and Human Services, mandating strict compliance measures to avoid future violations.

The deal removes the risk of exclusion from Medicare and Medicaid programs, a potential significant impact for pharmaceutical companies reliant on federal reimbursement. The settlement stems from allegations that EyePoint’s practices for DEXYCU violated the False Claims Act by inducing improper billing to Medicare, Medicaid, and TRICARE. The company previously paid approximately $500,000 to ambulatory surgery centers, which offered free or discounted DEXYCU units when commercial insurers denied reimbursement.

Compliance Overhaul Required

Under the Corporate Integrity Agreement, EyePoint must appoint a Compliance Officer, establish a Compliance Committee, and implement board-level oversight of federal healthcare compliance. The agreement also mandates annual risk assessments, independent reviews, and employee screening to ensure no excluded individuals participate in federal health programs. Failure to comply could trigger monetary penalties or exclusion from Medicare and Medicaid.

The company will use cash on hand to fund the settlement.

Market Reaction

Shares of EyePoint showed little immediate reaction to the news. The settlement removes a regulatory concern that had weighed on investor sentiment, though the financial impact and ongoing compliance costs could pressure margins. Analysts note that DEXYCU, the drug at the center of the probe, is no longer commercially marketed in the U.S. limiting direct revenue impact.

However, the case underscores broader risks in pharmaceutical marketing practices, particularly around sampling and reimbursement strategies.

Next Steps for Investors

EyePoint must complete the settlement payment, with the relator’s share and legal fees due within a specified timeframe. Investors will also watch for updates on EyePoint’s pipeline, including its sustained-release platforms for retinal diseases, which remain the primary growth drivers. The company’s disclosure suggests heightened regulatory scrutiny, making future compliance a key focus for management.

Based on the company’s SEC filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.